Physician profile
Janet E Shepherd
NPI 1255546222
$288,046.23
in general payments reported to CMS, 2019-2025
5 companies · $20K in 2025
The $20K reported for 2025 was more than what 97% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92K · 2020: $42K · 2021: $13K · 2022: $42K · 2023: $38K · 2024: $39K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $51K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $38K · Travel and Lodging: $6,555 · Food and Beverage: $2,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,792.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $37,947.04 |
| Travel and Lodging | $6,555.27 |
| Food and Beverage | $2,739.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $138,865.61 | 2019-2021 | |
| Organon LLC | $89,596.17 | 2021-2025 | Nexplanon |
| Astellas Pharma US INC | $57,696.42 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $1,848.17 | 2019-2025 | |
| Astellas Pharma Global Development | $39.86 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Shepherd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.